查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1464742

急性呼吸窘迫症候群市场：按类型、原因和最终用户划分 - 全球预测 2024-2030

Acute Respiratory Distress Syndrome Market by Type (Diagnostics, Treatment), Cause (Direct Lung Injury, Indirect Lung Injury), End-user - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年急性呼吸窘迫症候群市场规模为25.6亿美元，预计2024年将达27.2亿美元，2030年将达38.9亿美元，复合年增长率为6.13%。

急性呼吸窘迫症候群（ARDS）是一种严重的肺部疾病，其特征是肺部快速发生广泛的发炎。 ARDS 是一种呼吸衰竭，当液体在肺部的小弹性气囊（肺泡）中积聚时就会发生。这种液体会阻止肺部充满足够的空气，因此到达血液的氧气就会减少。 ARDS 市场的产品和服务应用于重症加护环境，例如加护病房(ICU) 和医院急诊室，治疗严重呼吸衰竭患者。有几个因素正在影响 ARDS 市场的成长。 ARDS 盛行率的不断增加，加上败血症、创伤和感染疾病的增加，正在推动对有效治疗方法的需求。机械通气和支援护理方面的技术进步正在促进市场成长。此外，医疗保健专业人员对新药研发的日益关注以及对 ARDS 的认识和理解不断增强，也正在推动市场向前发展。儘管预计会成长，但 ARDS 市场面临着治疗成本高和低收入地区获得先进医疗服务有限等挑战，限制了市场扩张。此外，ARDS 的复杂性、患者对治疗的不同反应以及对病理生理学的了解不足，使普遍有效的治疗方法的开发变得复杂。另一方面，针对 ARDS 分子和免疫学基础的个人化医疗方法的开发提供了巨大的商机。此外，随着医疗基础设施投资的增加，新兴市场的扩张也提供了新的成长途径。学术和研究机构与工业界在开发创新治疗方法方面的合作也正在扩大潜力。

主要市场统计
基准年[2023] 25.6亿美元
预测年份 [2024] 27.2亿美元
预测年份 [2030] 38.9亿美元
复合年增长率（%） 6.13%

类型：可望应用于精准医疗，诊断需求不断增加

ARDS 的准确诊断对于及时开始治疗至关重要。诊断领域主要分为诊断影像、血液检测和分子诊断。诊断影像主要包括胸部 X 光检查和电脑断层扫描，以检测肺泡内是否有液体。 电脑断层扫描提供详细的影像，有助于区分 ARDS 和其他疾病。血液检查用于测量氧气水平并识别潜在的感染疾病。血液检查对于诊断 ARDS 至关重要，但仅靠血液检查并不能确诊病情。由于其早期检测和严重性评估的潜力，该领域预计将会成长。 ARDS 的治疗方法多种多样，包括机械通气、药物治疗和实验治疗。机械通气是 ARDS 患者的重要介入措施，有助于维持氧合。飞利浦医疗保健和美Medtronic的高端人工呼吸器因其先进的功能而备受青睐，可最大限度地提高患者舒适度并改善治疗结果。药物包括皮质类固醇和抗生素，分别用于控制发炎和感染疾病。实验性治疗包括干细胞疗法和 ECMO（体外膜氧气疗法）。儘管仍在研究中，但这些治疗方法显示出改善 ARDS 预后的潜力。 ARDS 市场显示出巨大的成长潜力，其进步主要体现在诊断领域，特别是分子诊断，因为其在精准医疗中的潜在应用。然而，与尖端诊断影像设备和先进治疗设备相关的高成本可能会给某些市场带来可近性挑战。治疗性介入，特别是机械通气和实验治疗，正在经历创新性的改进，以提高患者的生存率并最大限度地减少併发症。

最终用户：扩大医院对 ARDS 管理的偏好

医院是治疗 ARDS 的前线战士，提供从机械通气到体外膜氧合 (ECMO) 的全面护理。医院基于需求的偏好主要围绕在提供多学科护理和先进生命维持管理系统的能力。专注于肺部和呼吸护理的专科诊所为 ARDS 管理提供专门服务，包括但不限于肺部復健和标靶治疗。这些诊所为需要长期急性后专门治疗的 ARDS 患者以及轻度至中度 ARDS 患者提供服务。由于其规模和设施齐全，医院通常设备齐全，可以处理需要多专科干预和高级支援护理的严重 ARDS 病例。医院具有整合不同专业的优势，确保对病人进行整体管理。

区域洞察

美洲，特别是美国和加拿大，对急性呼吸窘迫症候群(ARDS) 的先进治疗有巨大需求。这些地区 ARDS 的高盛行率，加上强大的医疗基础设施，正在推动市场的显着成长。美洲客户的购买行为倾向于创新和实证治疗，反映出他们对先进医疗技术和药物干预措施的信任。在南美洲，ARDS治疗和诊断市场正在逐渐扩大，以巴西和阿根廷为首，这两个国家正在投资医疗基础设施和临床研究。欧洲是 ARDS 的重要市场，西欧国家在研究、治疗方法采用和市场收益方面处于领先地位。该地区受益于强大的医疗保健系统和先进治疗方法的广泛采用。此外，针对 ARDS 的众多措施和合作研究工作正在进行中，这增加了有效管理策略的迫切性。同时，中东和非洲面临独特的挑战，包括获得医疗服务的机会有限以及某些地区缺乏专门的医疗设施。但由于认识的提高和医疗费用的增加，这些地区的ARDS治疗情况正在逐渐改善。在医疗保健成本上升和人口成长的推动下，亚太地区 ARDS 治疗和诊断市场正在快速成长。中国、日本和印度由于人口众多且呼吸道疾病盛行率不断上升，正在推动这项成长。该地区的研究倡议和最先进治疗的采用也显着增加。政府改善医疗保健系统的倡议进一步推动亚太市场向前发展。

FPNV定位矩阵

FPNV 定位矩阵对于评估急性呼吸窘迫症候群症候群市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对急性呼吸窘迫症候群症候群市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.急性呼吸窘迫症候群市场的市场规模与预测是多少？

2.在急性呼吸窘迫症候群市场预测期内，有哪些产品、细分市场、应用和领域需要考虑投资？

3.急性呼吸窘迫症候群市场的技术趋势和法规结构是什么？

4.急性呼吸窘迫症候群市场主要供应商的市场占有率是多少？

5. 进入急性呼吸窘迫症候群症候群市场适合的型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 由于败血症、创伤和感染疾病发生率增加，ARDS 盛行率增加
      • 人工呼吸器和支持治疗的进展
      • 新药研发日益受到重视
    • 抑制因素
      • 治疗费用高昂，获得先进医疗服务的机会有限
    • 机会
      • 个人化医疗方法的持续发展
      • 政府措施和增加医疗基础设施投资
    • 任务
      • 核准新治疗方法和设备的监管复杂性；
  • 市场区隔分析
    • 类型：由于精准医学的潜在应用，诊断需求不断增加
    • 最终用户：扩大医院在管理 ARDS 方面的优先级
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章急性呼吸窘迫症候群市场：依类型

  • 诊断
  • 过程

第七章急性呼吸窘迫症候群市场：依原因分类

  • 直接肺损伤
  • 间接肺损伤

第八章急性呼吸窘迫症候群市场：依最终用户分类

  • 医院
  • 专科诊所

第九章美洲急性呼吸窘迫症候群市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区急性呼吸窘迫症候群市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲急性呼吸窘迫症候群市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 市场占有率分析（2023）
  • FPNV定位矩阵（2023）
  • 竞争场景分析
    • BioAegis 与 BARDA 签订 2000 万美元合同，开发 ARDS 治疗药物
    • Veru Inc. 同意 FDA 对 Sabavibrin 进行新的 III 期临床试验，其适应症广泛，适用于因所有类型的病毒性急性呼吸窘迫症候群(ARDS) 住院的成年患者
  • 战略分析和建议

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-4E447E7FCAAC

[196 Pages Report] The Acute Respiratory Distress Syndrome Market size was estimated at USD 2.56 billion in 2023 and expected to reach USD 2.72 billion in 2024, at a CAGR 6.13% to reach USD 3.89 billion by 2030.

Acute respiratory distress syndrome (ARDS) is a severe lung condition characterized by rapid onset of widespread inflammation in the lungs. ARDS is a type of respiratory failure that occurs when fluid is produced in the tiny, elastic air sacs (alveoli) in the lungs. The fluid controls the lungs from filling with sufficient air, which means less oxygen reaches the bloodstream. Products and services in the ARDS market are applied in critical care settings, including intensive care units (ICUs) in hospitals and emergency departments, where patients with severe respiratory failure receive treatment. Several factors influence the growth of the ARDS market. The increasing prevalence of ARDS, partly due to rising rates of sepsis, trauma, and infections, drives the demand for effective treatments. Technological advancements in mechanical ventilation and supportive therapies contribute to market growth. Additionally, the heightened focus on research and development of new pharmaceuticals and the expanding awareness and understanding of ARDS among healthcare providers propel the market forward. Despite growth prospects, the ARDS market faces challenges such as high treatment costs and limited accessibility to advanced care in low-income regions that restrict market expansion. Furthermore, the complexity of ARDS, variability in patient response to treatments, and a still-evolving understanding of its pathophysiology make developing universally effective treatments challenging. On the other hand, the development of personalized medicine approaches targeting the molecular and immunological underpinnings of ARDS presents a significant opportunity. Additionally, expanding markets in emerging economies, with increasing healthcare infrastructure investments, offer new avenues for growth. Collaboration between academic, research institutions, and industry in developing innovative therapies also opens up potential opportunities.

KEY MARKET STATISTICS
Base Year [2023] USD 2.56 billion
Estimated Year [2024] USD 2.72 billion
Forecast Year [2030] USD 3.89 billion
CAGR (%) 6.13%

Type: Increasing need for diagnostics due to its potential for precision medicine application

Accurate diagnosis of ARDS is pivotal for initiating timely treatment. The diagnostics segment is principally categorized into Imaging, Blood Tests, and Molecular diagnostics. Imaging primarily involves Chest X-rays and CT Scans to detect the presence of fluid in the alveoli. Need-based preference leans towards CT scans for their detailed imagery, aiding in the discernment of ARDS from other conditions. Blood tests are utilized for measuring oxygen levels and identifying potential infections. These are integral for ARDS diagnosis, though they cannot solely confirm the condition. Molecular diagnostics focusing on genetic markers and biomarkers associated with ARDS. This segment is expected to grow, given its potential for early detection and assessment of disease severity. Treatment modalities for ARDS are diverse, encompassing Mechanical Ventilation, Drug Therapy, and Experimental Therapies. Mechanical ventilation is a crucial intervention for ARDS patients, helping maintain oxygenation. High-end ventilators from Philips Healthcare and Medtronic are highly preferred for their advanced features, which maximize patient comfort and improve outcomes. Drug therapy includes corticosteroids and antibiotics, among other medications, to manage inflammation and infections, respectively. Experimental therapies include stem cell therapy and ECMO (Extracorporeal Membrane Oxygenation). While still under investigation, these treatments show promise for improving ARDS outcomes. The ARDS market exhibits significant growth potential, with advancements predominantly observed in the diagnostics segment, particularly in molecular diagnostics, due to its potential for precision medicine applications. However, the high costs associated with state-of-the-art imaging equipment and advanced therapeutic devices could pose accessibility challenges in certain markets. Treatment interventions, specifically mechanical ventilation and experimental therapies, are witnessing innovative enhancements to improve patient survival rates and minimize complications.

End-user: Expanding preference for hospitals for management of ARDS

Hospitals are the frontline warriors in the management of ARDS, providing comprehensive care ranging from mechanical ventilation to extracorporeal membrane oxygenation (ECMO). The need-based preference in hospitals primarily revolves around the capability to offer multi-disciplinary care and advanced life support systems. Specialty Clinics focusing on pulmonary and respiratory care offer specialized services for ARDS management, including but not limited to pulmonary rehabilitation and targeted medical therapies. These clinics cater to ARDS patients with a need for prolonged, specialized care post-acute phase or those with mild to moderate ARDS. Hospitals, given their scale and comprehensive facilities, are often better equipped to manage severe cases of ARDS that require multi-specialty intervention and advanced supportive care. They benefit from the integration of various specialties, ensuring a holistic approach to patient management.

Regional Insights

The Americas, particularly the United States and Canada, have shown a significant need for advanced treatments for acute respiratory distress syndrome (ARDS). The high prevalence of ARDS in these regions, compounded by robust healthcare infrastructure, has facilitated substantial market growth. Customer purchasing behavior in the Americas tends to lean towards innovative, evidence-based treatments, reflecting a trust in advanced medical technology and pharmaceutical interventions. In South America, the market for ARDS treatments and diagnostics is gradually expanding, with Brazil and Argentina at the forefront, investing in healthcare infrastructure and clinical research. Europe represents a significant market for ARDS, with Western European countries are at forefront in terms of research, treatment adoption, and market revenues. The region benefits from strong healthcare systems and widespread adoption of advanced therapeutics. Moreover, numerous initiatives and collaborations aim to address ARDS, elevating the urgency for effective management strategies. In contrast, the Middle East and Africa face distinctive challenges, including limited access to healthcare services and a lack of specialized medical facilities in some areas. However, growing awareness and increasing healthcare expenditures are gradually improving the ARDS treatment landscape in these regions. The Asia-Pacific region is witnessing rapid market growth for ARDS treatments and diagnostics, fueled by rising healthcare spending and population growth. China, Japan, and India are conducting this growth due to their large populations and increasing prevalence of respiratory diseases. The region is also seeing a significant uptick in research initiatives and adoption of cutting-edge treatments. Government initiatives to improve healthcare systems are further propelling the market forward in the APAC region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Acute Respiratory Distress Syndrome Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Acute Respiratory Distress Syndrome Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Acute Respiratory Distress Syndrome Market, highlighting leading vendors and their innovative profiles. These include APEPTICO GmbH, Armstrong Medical Ltd., Athersys, Inc., Bayer AG, Besmed Health Business Corp., Dragerwerk AG & Co. KGaA, EUROSETS S.R.L., F. Hoffmann-La Roche Ltd., Fisher & Paykel Healthcare Corporation Limited, GE HealthCare, Getinge AB, Hamilton Medical AG, HEALIOS K.K., LivaNova PLC, Novartis AG, NRx Pharmaceuticals, Pfizer Inc., Sun Pharmaceutical Industries Limited, Terumo Medical Corporation, United Therapeutics Corporation, and WEINMANN Emergency Medical Technology GmbH + Co. KG.

Market Segmentation & Coverage

This research report categorizes the Acute Respiratory Distress Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Diagnostics
    • Treatment
  • Cause
    • Direct Lung Injury
    • Indirect Lung Injury
  • End-user
    • Hospital
    • Speciality Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Acute Respiratory Distress Syndrome Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Acute Respiratory Distress Syndrome Market?

3. What are the technology trends and regulatory frameworks in the Acute Respiratory Distress Syndrome Market?

4. What is the market share of the leading vendors in the Acute Respiratory Distress Syndrome Market?

5. Which modes and strategic moves are suitable for entering the Acute Respiratory Distress Syndrome Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of ARDS, partly due to rising rates of sepsis, trauma, and infections
      • 5.1.1.2. Advancements in mechanical ventilation and supportive therapies
      • 5.1.1.3. Rising focus on research and development of new pharmaceuticals
    • 5.1.2. Restraints
      • 5.1.2.1. High treatment costs and limited accessibility to advanced care
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing development of personalized medicine approaches
      • 5.1.3.2. Increasing government initiatives and healthcare infrastructure investments
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory complexities for the approval of new therapies and devices
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Increasing need for diagnostics due to its potential for precision medicine application
    • 5.2.2. End-user: Expanding preference for hospitals for management of ARDS
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Acute Respiratory Distress Syndrome Market, by Type

  • 6.1. Introduction
  • 6.2. Diagnostics
  • 6.3. Treatment

7. Acute Respiratory Distress Syndrome Market, by Cause

  • 7.1. Introduction
  • 7.2. Direct Lung Injury
  • 7.3. Indirect Lung Injury

8. Acute Respiratory Distress Syndrome Market, by End-user

  • 8.1. Introduction
  • 8.2. Hospital
  • 8.3. Speciality Clinics

9. Americas Acute Respiratory Distress Syndrome Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Acute Respiratory Distress Syndrome Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Acute Respiratory Distress Syndrome Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. BioAegis scores USD 20millon BARDA contract to develop ARDS therapy
    • 12.3.2. Veru Inc., Reaches Agreement With FDA on a New Phase III Clinical Trial for Sabizabulin for Broader Indication Hospitalized Adult Patients with any Type of Viral Acute Respiratory Distress Syndrome ARDS
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET RESEARCH PROCESS
  • FIGURE 2. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET DYNAMICS
  • FIGURE 7. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TREATMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TREATMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY DIRECT LUNG INJURY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY DIRECT LUNG INJURY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INDIRECT LUNG INJURY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INDIRECT LUNG INJURY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY HOSPITAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY SPECIALITY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY SPECIALITY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 26. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 27. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 28. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 29. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 30. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 34. ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 36. ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 38. ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 39. BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 40. BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 41. BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 42. BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 43. BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 44. BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 45. CANADA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 46. CANADA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 47. CANADA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 48. CANADA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 49. CANADA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 50. CANADA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 51. MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 54. MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 55. MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 56. MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 60. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 61. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 62. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 63. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 64. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 76. AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 78. AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 79. CHINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. CHINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. CHINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 82. CHINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 83. CHINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 84. CHINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 85. INDIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. INDIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. INDIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 88. INDIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 89. INDIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 90. INDIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 91. INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 94. INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 95. INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 96. INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 97. JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 100. JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 101. JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 102. JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 103. MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 106. MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 107. MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 108. MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 109. PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 112. PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 114. PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 115. SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 118. SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 119. SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 120. SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 121. SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 124. SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 126. SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 127. TAIWAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. TAIWAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. TAIWAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 130. TAIWAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 131. TAIWAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 132. TAIWAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 133. THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 136. THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 137. THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 138. THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 139. VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 142. VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 143. VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 144. VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 153. DENMARK ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. DENMARK ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. DENMARK ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 156. DENMARK ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 157. DENMARK ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 158. DENMARK ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 159. EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 162. EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 163. EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 164. EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 165. FINLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. FINLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. FINLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 168. FINLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 169. FINLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 170. FINLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 171. FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 174. FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 175. FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 176. FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 177. GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 180. GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 181. GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 182. GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 183. ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 186. ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 187. ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 188. ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 189. ITALY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. ITALY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. ITALY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 192. ITALY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 193. ITALY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 194. ITALY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 195. NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 198. NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 200. NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 201. NIGERIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. NIGERIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. NIGERIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 204. NIGERIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 205. NIGERIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 206. NIGERIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 207. NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 210. NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 211. NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 212. NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 213. POLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. POLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. POLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 216. POLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 217. POLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 218. POLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 219. QATAR ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. QATAR ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. QATAR ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 222. QATAR ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 223. QATAR ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 224. QATAR ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 225. RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 228. RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 229. RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 230. RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 231. SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 234. SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 236. SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 237. SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 240. SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 242. SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 243. SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 244. SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 245. SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 246. SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 247. SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 248. SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 249. SWEDEN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. SWEDEN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. SWEDEN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 252. SWEDEN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 253. SWEDEN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 254. SWEDEN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 255. SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 258. SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 260. SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 261. TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 264. TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 265. TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 266. TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 267. UNITED ARAB EMIRATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. UNITED KINGDOM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 276. UNITED KINGDOM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED KINGDOM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 279. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 280. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023